![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF
in Treatment-naïve HIV-1 Infected Patients:
Week 96 Results
|
|
|
Reported by Jules Levin
Glasgow 2012 Nov 11-15
JK Rockstroh1, E DeJesus2, K Henry3, J-M Molina4, J Gathe5,
X Wei6, M Fordyce6, MS Rhee6, J Szwarcberg6
1University of Bonn, Bonn, Germany, 2Orlando Immunology Center, Orlando, FL, US,
3Hennepin County Medical Center, Minneapolis, MN, US, 4Saint Louis Hospital, Paris, France,
5Therapeutic Concepts P.A., Houston, TX, US, 6Gilead Sciences, Foster City, CA, US
![Glasgow1.gif](../images/111612/111612-8/Glasgow1.gif)
![Glasgow2.gif](../images/111612/111612-8/Glasgow2.gif)
![Glasgow3.gif](../images/111612/111612-8/Glasgow3.gif)
![Glasgow4.gif](../images/111612/111612-8/Glasgow4.gif)
![Glasgow5.gif](../images/111612/111612-8/Glasgow5.gif)
![Glasgow6.gif](../images/111612/111612-8/Glasgow6.gif)
![Glasgow7.gif](../images/111612/111612-8/Glasgow7.gif)
![Glasgow8.gif](../images/111612/111612-8/Glasgow8.gif)
![Glasgow9.gif](../images/111612/111612-8/Glasgow9.gif)
![Glasgow10.gif](../images/111612/111612-8/Glasgow10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|